PresentationOperator Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related Macular Degeneration. Please note that this call is being recorded. [Operator Instructions] I would now like to turn the call to Tiffany Hamilton, Ocugen's Head of Corporate Communications. Please go ahead. ...